
Single access Ostomy, measuring recovery in days, not weeks.
Starting with inoperable patients, built to replace the standard of care.


For patients requiring bowel diversion or decompression, ostomy creation requires surgery under general anesthesia.
Up to $70k in total cost of care per surgical ostomy case.
Up to 55k high-risk and frail patients per year where surgery is not an option.
According to current CMS reporting.
*per annum, US only

PercStoma is designed to create an ostomy through a single access point, using a patent pending fixation device and proprietary stent.
The stent delivery system is introduced through the abdominal wall into the bowel using fluoroscopy.
The internal stent skirt is deployed in the bowel, followed by the external one.
A safe and patent artificial cannula is created, forming an ostomy prosthesis.


Phantom GI is starting with patients who cannot undergo surgery. The broader ambition is to establish minimally invasive ostomy creation as an alternative to surgical ostomy across indications — achieving the same clinical objective with significantly less intervention.
With no current treatment option for these patients, they suffer a grim prognosis measured in weeks.
Patients currently undergoing surgical diverting ostomies can access a safer and cleaner treatment, with half the healthcare costs.
Patients who currently aren't considered for ostomy due to the invasive nature of surgery can finally be treated with a minimally invasive approach.

Expert in minimally invasive medical devices.

Surgeon and radiologist with deep clinical expertise.

Physician with extensive startup experience.

Pioneer of minimally invasive surgery. Former SAGES President. 350+ publications.
A distinguished medical advisor will be joining the board soon.

The strategic engine behind Israel's globally renowned tech ecosystem.
Canada's largest research and teaching hospital network, advancing clinical innovation.
Phantom GI is engaging clinicians, investigators, clinical centers, strategic partners and investors as PercStoma advances toward clinical evaluation.